Those who feel betrayed by the recent decision of the Supreme Court to abandon the reasoning in Roe v. Wade (1973) and its extension Casey v. Planned Parenthood (1992) have a point. American women have relied on these decisions for many decades and felt, as time went on, that the precedents these two cases represented could be relied upon in perpetuity. Reliance alone is a justification for the judicial restraint expected of the Supreme Court of the United States.
American women, however, are not the only ones who have been affected by the principle of reliance relative to Roe and Casey. Elective abortions represent billions of dollars to businesses, educational in- stitutions, government employees, and third-party providers who profit from the use of elective abor- tion fetal tissue. The following are some of those entities:
- The flavoring chemical industry uses the HEK-293 cell line from an elective abortion to test taste receptors that allow the food industry to create artificial tastes in processed foods. Senomyx is an in- dustry leader and has contracted with many large food processors who then add the tested chemicals to their food products as taste enhancers. (Pepsi, Coca-Cola, Frito-Lay, Nestle, Starbucks, Nabisco, etc.)
- Big Pharma players such as Merck, GlaxoSmithKline, Amgen, Pfizer, Genetech, and others use elective abortion tissue cells for vaccine research and manufacture. Neocutis uses this tissue for beauty serums. Advanced Bioscience Resources sells fetal tissue from elective abortions and charges large sums for “collection, storage, processing and shipping” in light of federal law that prohibits profit from these sales. Some universities provide and use elective abortion fetal tissue as do abortion providers.
- The National Institutes of Health, the Center for Disease Control, and the National Institute of Al- lergy and Infectious Disease give research grants for research that includes elective abortion tissue as long as the mother gives her consent. The following is from the NIH Grants Policy Statement:
“Human fetal tissue is defined as tissue or cells obtained from a dead human embryo or fetus after a spontaneous or induced abortion or stillbirth. . .The statute specifically prohibits any person from knowingly acquiring, receiving, or transferring any human fetal tissue for valuable consideration. The term “valuable consideration” is a concept similar to profit and does not include reasonable payment for costs associated with the collection, processing, preservation, storage, quality control, or trans- portation of these tissues. . .When obtaining primary human fetal tissue for research purposes, NIH ex- pects grantees and contractors to maintain appropriate documentation, such as an attestation from the health care provider or a third party supplier, that informed consent was obtained at the time of tissue collection.”
If a researcher working for the NIH contributes to a commercially viable and novel drug using fetal tis- sue from elective abortions, that employee may receive royalties in the millions of dollars over the life-time of the patent. With so much money involved in a commercial system that has relied on Roe and Casey, businesses could now be negatively impacted by a potential loss of available elective abortion tissue should many states restrict the procedure.